Clinical trial • Phase III • Infectious Disease
PfSPZ-LARC2 Vaccine for Malaria
Phase III trial of PfSPZ-LARC2 Vaccine for Malaria. 42 participants.
Overview
- Trial Therapeutic Area
- Infectious Disease
- Trial Disease
- Malaria
- Trial Stage
- Phase III
- Drug Modality
- Vaccine
Key dates
- Initial CTIS Submission Date
- 04-12-2025
- First CTIS Authorization Date
- 26-01-2026
Trial design
Phase III trial across 1 site in Germany.
- Target Sample Size
- 42
Eligibility
Recruits 42 Vulnerable population not selected; trial population described as healthy adult volunteers. No vulnerable population consent/assent handling is described in the available record..
- Vulnerable Population
- Vulnerable population not selected; trial population described as healthy adult volunteers. No vulnerable population consent/assent handling is described in the available record.
Recruitment
- Planned Sample Size
- 42
- Recruitment Window Months
- 3
- Consent Approach
- Informed consent to be provided by adult participants. Trial enrols healthy adults; no vulnerable population or assent procedures described. Languages or age-specific consent documents not specified in the available record.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 42
Germany
- Earliest CTIS Part Ii Submission Date
- 01-12-2025
- Latest Decision Or Authorization Date
- 25-03-2026
- Processing Time Days
- 114
- Number Of Sites
- 1
- Number Of Participants
- 42
Sites
- Site Name
- Universitaetsklinikum Tuebingen AöR
- Department Name
- Internal Medicine VII
- Principal Investigator Name
- Peter Kremsner
- Principal Investigator Email
- peter.kremsner@uni-tuebingen.de
- Contact Person Name
- Peter Kremsner
- Contact Person Email
- peter.kremsner@uni-tuebingen.de
- Number Of Participants
- 42
Sponsor
Primary sponsor
- Full Name
- Universitaetsklinikum Tuebingen AöR
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Germany
Investigational products
- Investigational Product Name
- PfSPZ-LARC2 Vaccine
- Modality
- Vaccine
Related trials
Other published trials that may interest you.
- INE963 for Malaria
- Plasmodium falciparum, strain NF54, sporozoites for Malaria
- Conditioned medium from a co-culture of M2-macrophages and fat-derived mesenchymal cells for Acute respiratory distress syndrome (ARDS) | SARS-CoV-2 infection | Influenza A infection | Influenza B infection | Respiratory syncytial virus (RSV) infection
- ACICLOVIR for Recurrent herpes labialis | Herpes simplex labialis
- AMIKACIN SULFATE for Sepsis | Neutropenia